Go Pro
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.25
+4.7%		$0.27
$0.18
▼
$1.45
$12.67M0.652.37 million shs661,539 shs
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$4.35
$4.34
$1.50
▼
$9.50
$3.23M-0.051,513 shsN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$3.83
+1.9%		$4.48
$0.94
▼
$7.76
$11.40M0.721.63 million shs8,276 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.77
-20.1%		$0.99
$0.74
▼
$12.23
$16.01M-1.687.33 million shs1.87 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
+4.74%-11.25%+32.22%-63.30%-66.71%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00%0.00%0.00%-17.92%-45.15%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00%-8.04%-21.19%-34.97%+187.97%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-20.06%-1.34%-25.60%-38.34%-92.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.25
+4.7%		$0.27
$0.18
▼
$1.45
$12.67M0.652.37 million shs661,539 shs
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$4.35
$4.34
$1.50
▼
$9.50
$3.23M-0.051,513 shsN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$3.83
+1.9%		$4.48
$0.94
▼
$7.76
$11.40M0.721.63 million shs8,276 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.77
-20.1%		$0.99
$0.74
▼
$12.23
$16.01M-1.687.33 million shs1.87 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
+4.74%-11.25%+32.22%-63.30%-66.71%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00%0.00%0.00%-17.92%-45.15%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00%-8.04%-21.19%-34.97%+187.97%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-20.06%-1.34%-25.60%-38.34%-92.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
2.80
Moderate Buy$1.33424.93% Upside
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00
N/AN/AN/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
0.00
N/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest ENZN, TPST, NTN, and AEON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$1.80
8/14/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00 ➝ $1.20
7/30/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$1.00
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$30K107.59N/AN/A($3.40) per share-1.28
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
$19.81M0.58$0.87 per share4.38$1.76 per share2.18
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M-$4.421.41N/AN/AN/AN/A-994.63%11/13/2026 (Estimated)
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
-$3.41M-$6.84N/AN/AN/AN/A-21.54%-7.22%N/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
-$2.05MN/AN/AN/AN/A-61.42%-162.54%-49.94%N/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest ENZN, TPST, NTN, and AEON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$0.122.76%N/AN/A N/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.42
2.01
1.16
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
3.30
0.95
0.95
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
6.31%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
9.40%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.40%
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
24.20%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
849.88 million74.37 millionNot Optionable
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A742,000739,000Not Optionable
NTN Buzztime, Inc. stock logo
NTN
NTN Buzztime
192.98 millionN/ANot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
416.54 million10.55 millionNo Data

Recent News About These Companies

Tempest Therapeutics (NASDAQ:TPST) Trading Down 20.1% - Here's What Happened
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037831
Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69591841-tempest-therapeutics-tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform-399.htm
Tempest Stock Exploded on a CAR-T Option Most Investors Had Never Heard Of
September 16, 2026  |  moneymorning.comM
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
September 16, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61809066/why-tempest-therapeutics-shares-are-trading-higher-by-around-50-here-are-20-stocks-moving-premarket?utm_source=snapi
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691311/tempest-gets-option-to-license-cd7-targeted-in-vivo-car-t-platform-overnight-stock-surge-64.aspx
Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Tempest+Therapeutics+options+CD7+lentiviral+CAR-T+platform+from+Senlang/27064842.html
Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tempest-therapeutics-gains-option-license-214530532.html
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362637/0/en/tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform.html
Tempest Therapeutics announces $2.5M private placement
September 11, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/tempest-therapeutics-announces-25m-private-placement/ar-AA2c1rwV
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360287/0/en/tempest-therapeutics-announces-up-to-7-5-million-private-placement.html
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357654/0/en/tempest-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
July 15, 2026  |  quiverquant.comQ
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html
Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  quiverquant.comQ
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307117/0/en/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Nutanix logo displayed on a server unit mounted within a data center equipment rack.
Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
By Thomas Hughes | August 27, 2026
AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.25 +0.01 (+4.74%)
As of 09/21/2026 03:59 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Enzon Pharmaceuticals stock logo

Enzon Pharmaceuticals OTCMKTS:ENZN

$4.35 0.00 (0.00%)
As of 09/18/2026

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

NTN Buzztime stock logo

NTN Buzztime NYSEAMERICAN:NTN

$3.83 +0.07 (+1.86%)
As of 09/18/2026

NTN Buzztime, Inc., together with its subsidiaries, provides interactive entertainment and technology to bars, restaurants, casinos, and senior living centers in the United States and Canada. Its principal product and service is its tablet platform. The company also leases equipment, including tablets, and cases and charging trays for the tablets to various network subscribers. It also licenses its content to customers to be installed on equipment that they obtain from other parties. The company's interactive entertainment system offers trivia, card, sports, and arcade games. It owns various trademarks, including the Buzztime, Playmaker, Mobile Playmaker, and BEOND Powered. As of June 30, 2020, NTN Buzztime, Inc. served 1,219 venues with its interactive entertainment network. The company was formerly known as NTN Communications, Inc. and changed its name to NTN Buzztime, Inc. in 2005. NTN Buzztime, Inc. was founded in 1982 and is based in Carlsbad, California.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.77 -0.19 (-20.06%)
As of 09/21/2026 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas